Essa Pharma

failure crash no fail rocket cancelled end

Essa drops lead cancer drug after falling short against Xtandi

Essa's sole clinical-stage candidate was on track to fall short in a phase 2 prostate cancer study, leading the biotech to “review strategic options.”

James Waldron Nov 1, 2024 7:33am

potion spooky halloween witches brew spell witch

Janssen can't conjure up patients for ESSA prostate cancer trial

Oct 31, 2022 10:20am

Pfizer invests $120M in 4 biotechs through new growth fund

Jan 12, 2021 8:55am

Essa to buy Realm, gaining cash to fund cancer R&D

May 16, 2019 9:45am